Eylea Pricing is Eye-Opening: Regeneron Plays to CMS, Payors on Price; Docs with Terms

Choosing between doctors and payors in the “buy-and-bill” sector used to be easy – price to the doctor’s advantage. The higher the price, the larger the spread and the happier the drug company. Regeneron is bending that model towards the reimbursers (and Medicare, in particular) with Eylea. Regenero

More from Pricing Debate

More from Market Access